Objectives To quantify the long-term comparative efficacy and safety of nivolumab in
combination with ipilimumab (NIVO+ IPI) relative to other immunotherapy (IO)-based …

Squamous cell carcinoma (SCC) of the lung has a markedly different molecular profile to
adenocarcinoma of the lung and remains difficult to treat because of the lack of targeted …

Patient-derived organoids (PDOs) are widely heralded as a drug-screening platform to
develop new anti-cancer therapies. Here, we use a drug-repurposing library to screen PDOs …

Importance The introduction of immune checkpoint inhibitors (ICIs) has transformed the care
of advanced non–small cell lung cancer (NSCLC). Although clinical trials suggest …

Objectives To describe the treatment patterns and determine the effectiveness and safety of
nivolumab treatment for non-small cell lung cancer (NSCLC) in real-world setting in Japan …

Objective: The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score and the
Geriatric Nutrition Risk Index (GNRI) are used as prognostic factors in different types of …

Gefitinib is tyrosine kinase inhibitor of epidermal growth factor receptor, which exhibits
notable clinical efficacy in non-small-cell lung cancer (NSCLC) treatment. However, gefitinib …

Nintedanib is a tyrosine kinase inhibitor of fibroblast growth factor-, vascular endothelial
growth factor-, and platelet-derived growth factor receptors. These three receptors promote …

ObjectiveThe Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score and the
Geriatric Nutrition Risk Index (GNRI) are used as prognostic factors in different types of …

Introduction Clinical evidence suggests that first-line immune checkpoint inhibitor (ICI)
combination therapies can improve survival in patients with advanced non-squamous non …